Peptides,without the hype.

In Phase 2, estimated mean weight loss at week 48 reached 17.1% in the combined 4-mg group, 22.8% at 8 mg and 24.2% at 12 mg. Later sponsor-reported Phase 3 data support continued development, but the molecule remains investigational.

GIP/GLP-1 agonism supports glucose-dependent insulin secretion, while the glucagon component adds an energy-expenditure dimension. Trials assess HbA1c, glucose, lipids and broader cardiometabolic markers.

Weight reduction has been accompanied by decreases in waist circumference and adiposity. Proper interpretation separates fat mass from lean mass rather than treating all lost weight as equivalent.

Phase 3 programmes have also explored obstructive sleep apnoea and knee osteoarthritis in people with obesity. These outcomes belong to the studied populations and endpoints, not to a general claim for the molecule.

A small retrospective knee-pain series reported subjective improvement after intra-articular injection. There was no comparator, uniform diagnosis or validated outcome tool, so efficacy cannot be established.

Animal models report improvements in structure, biomechanics and function after tendon, ligament and muscle injury, together with signals involving fibroblasts, VEGF and matrix remodelling.

Experimental literature includes mucosal protection and injury-response biology. FDA has also summarised older human experience with rectal formulations in early studies, which does not validate modern online uses.

Reported pathways include eNOS/nitric oxide, inflammatory signalling and angiogenesis. These are biologically plausible mechanisms, but no single validated receptor explains the full set of claims attributed to BPC-157.

Full-length thymosin β4 was studied topically in venous ulcers; a Phase 2 study suggested 0.03% might accelerate healing in selected wounds. This cannot be transferred automatically to fragments marketed as TB-500.

Tβ4 binds G-actin and participates in cytoskeletal dynamics, keratinocyte and endothelial migration, angiogenesis and tissue remodelling.

A first-in-human recombinant Tβ4 study characterised pharmacokinetics and tolerability of escalating intravenous doses in healthy volunteers. This describes Tβ4, not the identity of commercial TB-500 materials.

The Tβ4 family has been studied in several epithelial-repair settings. Benefits remain formulation- and molecule-specific and cannot be generalized to every derivative.

Topical studies and ex-vivo data suggest effects on collagen, elasticity, hydration and wrinkle appearance. Outcomes depend heavily on formulation, concentration and skin penetration.

A randomized study after CO₂ laser resurfacing evaluated skin-care regimens containing GHK-Cu. These are local topical data and do not support extrapolation to systemic use.

GHK-Cu binds copper and affects fibroblasts, collagen/elastin expression, metalloproteinases and oxidative-stress responses in experimental models.

A 2026 study of a cream containing 0.2% GHK-Cu plus 5% ferment reported improvements in selected hydration, wrinkle and pore measures after 56 days. The effect cannot be assigned to GHK-Cu alone.

GHRH analogues can increase GH secretion and subsequently IGF-1. Direct human evidence for the exact “No DAC” material is much thinner than for CJC-1295 with DAC.

The non-DAC form is used experimentally for shorter exposure and study of GHRH signalling. The commercial label “No DAC” is not universally standardized and may conceal sequence differences.

A rise in GH/IGF-1 does not automatically establish muscle gain, fat loss or better recovery. Robust clinical trials with the exact molecule are lacking for these outcomes.

CJC-1295 with DAC binds albumin and has a much longer duration. Its results cannot be treated as equivalent exposure for No DAC.

In healthy volunteers, ipamorelin produced a dose-related GH-release episode with a relatively rapid peak and subsequent return toward baseline.

It is a GH secretagogue acting at the ghrelin receptor/GHSR-1a and was developed for a more selective pharmacologic profile than earlier secretagogues.

GHSR agonists have also been investigated for gastrointestinal motility. These programmes did not establish a broad clinical benefit for ipamorelin.

A transient hormonal response is not evidence of muscle gain, fat loss or improved performance. Confirmatory clinical trials for those claims are lacking.

MOTS-c is a mitochondrial-derived peptide studied in models of insulin resistance, glucose use and metabolic adaptation, including AMPK-related signalling.

Endogenous MOTS-c levels have been studied in relation to exercise and age. Measuring the body’s own peptide is not equivalent to administering exogenous MOTS-c.

Research covers mitochondria-to-nucleus communication, energy homeostasis and stress responses. The clinical relevance of administering the peptide remains unestablished.

Animal models have generated hypotheses around metabolic resilience and late-life physical capacity, but there is no clinical evidence for an anti-aging effect in humans.

Elamipretide (FORZINITY) received accelerated U.S. approval to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. Benefit and dose belong to this product and indication.

The molecule binds cardiolipin in the inner mitochondrial membrane and is studied for effects on membrane organization, bioenergetics and oxidative stress.

Development programmes have included Barth syndrome and other mitochondrial phenotypes. Results are disease-specific and do not support general “energy” or longevity use.

Endpoints have included strength and physical-function measures. Extrapolation to healthy people or sports performance is not justified.

Randomized studies in people with HIV and abdominal fat accumulation showed significant reductions in VAT, sustained while treatment continued.

A 6-month RCT also reported a modest reduction in liver fat alongside VAT reduction. Long-term clinical importance depends on the population and outcome context.

Some studies reported reductions in triglycerides and improvements in selected metabolic parameters, alongside an increase in IGF-1.

Phase 3 studies included improvement in ratings of abdominal appearance/distress. This endpoint is specific to HIV-associated lipodystrophy.

The C-terminal GH region was studied for metabolic/lipolytic signalling without the full growth profile of GH. Most mechanistic evidence is animal-based.

AOD-9604, a modified analogue frequently conflated with HGH Frag 176-191, showed modest signals in smaller trials but a large Phase 2b programme failed to demonstrate sufficient weight loss versus placebo.

The AOD-9604 programme monitored glucose/insulin parameters and did not reproduce the full IGF-1 profile of GH. This does not establish weight-loss efficacy.

AOD-9604 is structurally modified and is not automatically identical to every “HGH Frag 176-191” product. Results cannot be transferred without sequence confirmation.

Russian ischemic-stroke studies reported improvements in selected neurologic and functional measures when Semax was added to standard therapy. The evidence base is regional and lacks the same multinational validation as FDA/EMA-approved therapies.

Rehabilitation studies associated administration with increased plasma BDNF. A neurotrophic biomarker by itself does not establish cognitive or neuroprotective benefit.

Experimental models support effects on oxidative stress, inflammation and neurotrophic gene expression. Translation into durable clinical outcomes remains incomplete.

Some studies reported better Barthel-index and motor-recovery trajectories, particularly within post-stroke rehabilitation programmes.

In a study of generalized anxiety disorder and neurasthenia, Selank was compared with medazepam and improvements were reported on psychometric scales.

Some reports describe antiasthenic and psychostimulant effects in addition to anxiolysis, but samples are small and the literature is regionally concentrated.

Research explores effects on GABAergic transmission, gene expression and peptide systems. These mechanisms do not equal broad clinical efficacy.

A small analysis described faster clinical response and EEG changes in a subset after a single dose, requiring independent replication.

Small insomnia studies reported selected improvements in sleep latency/efficiency, while many endpoints did not differ from placebo.

A very small crossover study reported increased sleep over a short post-infusion window and some later nocturnal sleep changes.

Some measures of tiredness changed in small studies without a consistent effect on subjective sleep quality.

Older reports explored withdrawal from alcohol/opioids, but designs and standards are too dated to support a modern indication.

KPV inhibits NF-κB/MAPK and reduces selected pro-inflammatory cytokines in cell models, motivating interest in gut and skin research.

In mouse colitis models KPV reduced inflammation; PepT1 appears involved in peptide uptake by epithelial and immune cells.

Epithelial protection and skin-inflammation models, including topical delivery systems, have been studied. There is no demonstrated clinical benefit in humans.

α-MSH fragments including KPV have been explored for antimicrobial activity and local repair, but effects are model-specific and do not define a clinical use.

Bremelanotide improved sexual-desire domain scores in Phase 3 trials of premenopausal women with HSDD and is U.S.-approved for that specific indication.

RECONNECT trials also assessed reduction in distress related to desire/arousal, a distinct endpoint from frequency of sexual activity.

It acts through central melanocortin receptors, a mechanism different from agents acting mainly through peripheral haemodynamics.

Approval does not automatically extend to men, other sexual dysfunctions or performance goals. Those uses require separate evidence.

Long R3 IGF-1 activates IGF-1R and PI3K–AKT/MAPK pathways and is used to study proliferation, survival and cell differentiation.

Structural changes reduce binding to some IGF-binding proteins, altering exposure/activity relative to endogenous IGF-1.

Although IGF-1 signalling is central to growth biology, no controlled human trial of IGF-1 LR3 has demonstrated hypertrophy or performance benefit.

The analogue is used in cell culture and experimental models for differentiation and signalling. Growth-pathway activation requires caution when extrapolating to humans.

Kisspeptin-10 can stimulate LH/FSH release via KISS1R/GnRH, demonstrating the central role of kisspeptin signalling in human reproductive physiology.

The hormonal response has supported kisspeptin development as a tool in assisted reproduction. Many clinical programmes, however, use kisspeptin-54, which is not identical to kisspeptin-10.

Responses differ between men and women and across menstrual-cycle phases, showing that there is no universal dose-response relationship.

Controlled administration can probe GnRH sensitivity and LH dynamics, making it a translational research tool rather than a standardized therapy.

Epitalon is studied for effects on hTERT/telomerase and telomere length in cell culture. This does not demonstrate life extension or slower aging in humans.

Pineal-peptide literature reports effects on melatonin and circadian rhythms, but much human evidence concerns Epithalamin extract rather than synthetic Epitalon.

An older report from the originator group evaluated Epitalon in retinitis pigmentosa. Independent replication and a modern development programme are lacking.

Longevity claims rely mainly on animal models, cells and studies of related pineal preparations. No modern RCT demonstrates human life extension with Epitalon.

RCTs evaluated thymosin alpha-1 in chronic HBV, with some signals for sustained virologic response. Results vary and current standards of care have evolved.

An RCT in HBV-ACLF reported fewer new infections and hepatic encephalopathy with Tα1, while survival analyses require careful interpretation.

Tα1 is studied for modulation of innate/adaptive immunity, including dendritic-cell maturation and T-cell function.

It has been studied as an adjunct in multiple diseases and is authorized in some countries for selected indications. “Immunomodulator” does not mean universally beneficial stimulation.

GLP-1 augments insulin secretion when glucose is elevated, a central component of the incretin effect.

Native GLP-1 infusion studies in type 2 diabetes demonstrated improved glycaemia and changes in pancreatic hormone secretion.

GLP-1 slows gastric emptying and influences central satiety circuits. These effects motivated long-acting GLP-1 analogues.

Semaglutide and other GLP-1 receptor agonists are pharmacologically modified analogues. Their outcomes and doses must not be assigned directly to native GLP-1.